Leveraging psychedelic therapies for binge eating disorder
Open Access Government – July 10, 2023
Source: OpenAlex
Summary
Revolutionizing Psychiatry, a novel approach aims to harness the therapeutic power of psilocybin, a potent hallucinogen, for severe eating disorders. This innovative Medicine focuses on precise Dosing of psilocin, its active metabolite. Through intravenous administration, Pharmacology ensures consistent drug levels, overcoming oral psilocybin's variability in Psychedelics and Drug Studies. This method, influencing Neurotransmitter Receptor activity, offers a reliable path for Psychology, addressing complex conditions like binge-eating disorder and bulimia nervosa, where Tryptophan and brain disorders play a role.
Abstract
Leveraging psychedelic therapies for binge eating disorder Here Tryp Therapeutics examine the viability of using psychedelic therapies for Binge Eating Disorder and the potential results that using psychedelic-assisted psychotherapy could have on different eating disorders. Tryp Therapeutics is a clinical-stage biotechnology company dedicated to the development of exclusive and innovative formulations for administering psilocin in conjunction with psychotherapy, aiming to address unmet medical needs in various diseases. Our primary focus is on our lead program, TRP-8803, which represents a proprietary formulation of intravenous (IV) infused psilocin, the active metabolite of psilocybin. This formulation overcomes several limitations associated with oral psilocybin administration. By directly administering psilocin via the intravenous route, we achieve the most precise form of dosing, ensuring the reproducibility of blood levels necessary for clinical efficacy while preserving safety. In contrast, oral administration of psilocybin relies on enzymatic conversion of psilocybin to psilocin, resulting in substantial variability in drug blood levels among patients, potentially confounding the planned outcome of clinical studies.